ReviewDiscover oncology2026
Crosstalk between circRNAs and the MAPK signaling pathway in cancer progression.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Noncoding RNAs (ncRNAs), including long noncoding RNAs (lncRNAs), circular RNAs (circRNAs), and small ncRNAs, play critical roles in regulating biological processes and disease development. Among these, circRNAs, characterized by their single-stranded, covalently closed structures, act as protein templates, microRNA sponges, and transcriptional regulators, exhibiting high stability and distinct expression profiles. CircRNAs play an important role in several diseases, including autoimmune disorders, cardiovascular diseases, neurological conditions, and cancers. In cancer, they influence key mechanisms like cell cycle development, angiogenesis, apoptosis, proliferation, motility, and metastasis. Meanwhile, the mitogen-activated protein kinase (MAPK) signaling pathways—especially the Ras/Raf/MEK/ERK cascade—are central to controlling cell survival, proliferation, and tumor development, with hyperactivation of ERK linked to cancer progression. Despite the important roles of both circRNAs and MAPK pathways in oncogenesis, the mechanisms underlying their interplay remain poorly understood. This review aims to fill this knowledge gap by examining the bidirectional interactions between circRNAs and MAPK signaling in cancer and explores therapeutic implications, focusing on strategies such as circRNA modulation (targeting their functions as transcriptional regulators or microRNA sponges) and MAPK pathway inhibition to control cancer progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.